Mixed results from Precision HD 2 trial likely to impact the prospects of Wave Life Sciences
Wave Life Sciences (NASDAQ: WVE), a clinical-stage Company developing novel stereopure oligonucleotides to treat genetic defects, announced topline data from an ongoing Phase 1b/2a PRECISION-HD2 trial evaluating the safety and efficacy of WVE-120102, a first-in-class allele-selective approach to treat Huntington’s disease (HD). The study shows...
